Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
John S Yu Insider Profile
4 Followers
John S Yu, Director at ImmunoCellular Therapeutics, holds 5.34M shares in Kairos Pharma, Ltd. (Ticker: KAPA), holds 120.51K shares in ImmunoCellular Therapeutics (Ticker: IMUC). Most recently, John S Yu Bought ― shares of Kairos Pharma, Ltd. on Nov 21, 2024 for an estimated value of 5.76K.
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-24.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that John S Yu holds in companies
Most Profitable Insider Trade
The most profitable trade made by John S Yu
John S Yu's Trading History
ImmunoCellular Therapeutics
Jun 08, 2018
Director
Uninformative Buy
―
$20.49K
Kairos Pharma, Ltd.
Nov 21, 2024
CEO and Chairman, Director, Ten Percent Owner
Informative Buy
5.76K
$8.55M
List of latest transactions for each holding click on a transaction to see John S Yu's performance on stock
You May Also Like
John S Yu insider profile FAQ
What is the percentage of profitable transactions made by John S Yu?
The percentage of profitable transactions made by John S Yu is 25%.
What is the average return per transaction made by John S Yu?
The average return per transaction made by John S Yu is -24.10%.
What stocks does John S Yu hold?
John S Yu holds: IMUC, KAPA stocks.
What was John S Yu’s latest transaction?
John S Yu latest transaction was an Informative Buy of $5.76K.
What was John S Yu's most profitable transaction?
John S Yu’s most profitable transaction was an Informative Buy of KAPA stock on November 21, 2024. The return on the trade was 6.60%.
What is John S Yu's role in ImmunoCellular Therapeutics?
John S Yu's role in ImmunoCellular Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.